Literature DB >> 20638023

Antiviral therapy for chronic hepatitis B.

Syed-Mohammed R Jafri1, Anna Suk-Fong Lok.   

Abstract

The goal of antiviral therapy for chronic hepatitis B is to prevent the development of cirrhosis and hepatocellular carcinoma. End points, including viral suppression, alanine aminotransferase normalization, hepatitis B e antigen loss, hepatitis B surface antigen loss, and improvement in liver histology, are used to determine treatment success. Treatment is based on hepatitis B virus (HBV) replication status and stage of liver disease, modulated by the age of the patient, hepatitis B e antigen (HBeAg) status and patient preference. Seven therapies are approved, including two formulations of interferon and five orally administered nucleos(t)ide analogs. These therapies are effective in suppressing HBV replication and have also been shown to prevent disease progression. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20638023     DOI： 10.1016/j.cld.2010.05.005

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  9 in total

Review 1.  Noninvasive imaging assessment of portal hypertension.

Authors:  Paul Kennedy; Octavia Bane; Stefanie J Hectors; Aaron Fischman; Thomas Schiano; Sara Lewis; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2020-09-14

2.  Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system.

Authors:  Jason Lamontagne; Courtney Mills; Richeng Mao; Cally Goddard; Dawei Cai; Haitao Guo; Andy Cuconati; Timothy Block; Xuanyong Lu
Journal:  Antiviral Res       Date:  2013-02-13       Impact factor: 5.970

3.  Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells.

Authors:  Richeng Mao; Jiming Zhang; Dong Jiang; Dawei Cai; Jessica M Levy; Andrea Cuconati; Timothy M Block; Ju-Tao Guo; Haitao Guo
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

Review 4.  Screening and diagnosis of HBV in low-income and middle-income countries.

Authors:  Jean-Pierre Allain; Ohene Opare-Sem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

5.  Functional Characterization of Interferon Regulation Element of Hepatitis B virus Genome In Vivo.

Authors:  Feng-Jun Liu; En-Qiang Chen; Qiao-Ling Zhou; Tao-You Zhou; Cong Liu; Li Liu; Xing Cheng; Hong Tang
Journal:  Indian J Virol       Date:  2012-09-06

6.  Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.

Authors:  Thomas Schluep; Jason Lickliter; James Hamilton; David L Lewis; Ching-Lung Lai; Johnson Yn Lau; Stephen A Locarnini; Robert G Gish; Bruce D Given
Journal:  Clin Pharmacol Drug Dev       Date:  2016-12-12

Review 7.  Drugs in Development for Hepatitis B.

Authors:  Altaf Dawood; Syed Abdul Basit; Mahendran Jayaraj; Robert G Gish
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

Review 8.  Application of CRISPR/Cas9 Technology to HBV.

Authors:  Guigao Lin; Kuo Zhang; Jinming Li
Journal:  Int J Mol Sci       Date:  2015-11-02       Impact factor: 5.923

Review 9.  Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence.

Authors:  Ruth Byrne; Ivana Carey; Kosh Agarwal
Journal:  Therap Adv Gastroenterol       Date:  2018-07-16       Impact factor: 4.409
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.